Scarica l'app Stockscreener
2.05
5.09%
-0.11
Dopo l'orario di chiusura:
2.04
-0.010
-0.49%
Precedente Chiudi:
$2.16
Aprire:
$2.08
Volume 24 ore:
48,364
Relative Volume:
0.11
Capitalizzazione di mercato:
$169.71M
Reddito:
$47.04M
Utile/perdita netta:
$-63.98M
Rapporto P/E:
-2.5422
EPS:
-0.8064
Flusso di cassa netto:
$-34.39M
1 W Prestazione:
-32.12%
1M Prestazione:
+21.63%
6M Prestazione:
-4.21%
1 anno Prestazione:
-23.65%
Intervallo 1D:
$2.025
$2.10
Intervallo di 1 settimana:
$2.025
$2.67
Portata 52W:
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
Nome
Innate Pharma Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta IPHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
2.05 | 169.71M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | Iniziato | Goldman | Neutral |
Innate Pharma Adr Borsa (IPHA) Ultime notizie
Nebius Group N.V (NASDAQ: NBIS)’s Upward Trend Continues - Stocks Register
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies By Investing.com - Investing.com UK
Earnings call: Innate Pharma reports progress in drug development - Investing.com India
Earnings call: Innate Pharma reports progress in oncology pipeline - Investing.com
Innate Pharma S.A. ADR (IPHA-Q) QuotePress Release - The Globe and Mail
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update - The Globe and Mail
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update - The Globe and Mail
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag - Yahoo Movies UK
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting - Investing.com India
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities News
IPHA stock surges on upcoming presentation for AstraZeneca-partnered asset - Seeking Alpha
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Innate Pharma Adr Azioni (IPHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):